白细胞介素28B的基因多态性与丙型肝炎病毒感染转归的关系

石晓东; 姜晶; 牛俊奇

白细胞介素28B的基因多态性与丙型肝炎病毒感染转归的关系

1. 吉林大学白求恩第一医院肝胆胰内科
2. 吉林大学白求恩第一医院临床流行病学研究中心

详细信息

中图分类号: R512.63
计量
- 文章访问数: 8616
- HTML全文浏览量: 32
- PDF下载量: 2407
- 被引次数: 0
出版历程
- 出版日期: 2011-01-20

Association of interleukin 28B(IL28B) polymorphisms with the outcomes of HCV infection

摘要

摘要:
丙型肝炎病毒(HCV)急性感染的患者,大约30%发生自发清除,已经进展为慢性丙型肝炎(CHC)的患者,经过抗病毒治疗,大约40%得到持久的HCV清除。近年来宿主基因变异在HCV感染治疗中的关键作用备受瞩目。今就近期的国内外报道,对白细胞介素(IL)28B的基因变异与HCV感染转归的关系进行综述。
- 肝炎,丙型 /
- 白细胞介素类 /
- 多态现象,遗传
Abstract:
Hepatitis C Virus(HCV) infection is spontaneously resolved in about 30% of acutely infected individuals.In those who progress to chronic hepatitis,HCV therapy permanently eradicates infection in about 40% of cases.It has long been suspected that host genetic factors are key determinants for the control of HCV infection.In this study,we will review the relationship between genetic variation in interleukin 28B(IL28B) and the control of HCV infection.
- hepatitis C /
- interleukins /
- polymorphism

HTML全文

参考文献(22)

[1]World Health Organization.Hepatitis C 2009,http://www.who.int/mediacentre/factsheets/fs164/cn.2002 Nov;36(5 Suppl 1):S35-46.

[2]Seeff LB.Natural history of chronic hepatitis C[J].Hepatology,2002,36(5 Suppl 1):S35-46.

[3]McHutchison JG,Everson GT,Gordon SC,et al.Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection[J].N Engl J Med,2009,360(18):1827-1838.

[4]Shiffman ML,Lawitz EJ,Zaman A,et al.PEG-IFN-l:antiviral activity and safety profile in a 4-week phase 1b study in relapsed genotype 1 hepatitis C infection[J].Hepatology,2009,50(Suppl1):S237.

[5]Kenny-Walsh E.Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin.Irish Hepatology Research Group[J].N Engl J Med,1999,340(16):1228-1233.

[6]Muller R.The natural history of hepatitis C:clinical experiences[J].J Hepatol,1996,24(2 Suppl):52-54.

[7]Sheppard P,Kindsvogel W,Xu W,et al.IL-28,IL-29 and their class II cytokine receptor IL-28R[J].Nat Immunol,2003,4(1):63-68.

[8]Kotenko SV,Gallagher G,Baurin VV,et al.IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex[J].Nat Immunol,2003,4(1):69-77.

[9]Sommereyns C,Paul S,Staeheli P,et al.IFN-lambda(IFNlambda)is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo[J].PLoS Pathog,2008,4(3):e1000017.

[10]Ge D,Fellay J,Thompson AJ,et al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J].Nature,2009,461(7262):399-401.

[11]Kau A,Vermehren J,Sarrazin C.Treatment predictors of a sustained virologic response in hepatitis B and C[J].J Hepatol,2008,49(4):634-651.

[12]王东生,潘煜,牛俊奇,等.IL-28B基因变异与丙型肝炎的易感性及其自然清除的关系[J].临床肝胆病杂志,2010,26(5):496-499.

[13]McCarthy JJ,Li JH,Thompson A,et al.Replicated Association between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin[J].Gastroenterology,2010,138(7):2307-2314.

[14]Montes-Cano MA,García-Lozano JR,Abad-Molina C,et al.Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes[J].Hepatology,2010,52(1):33-37.

[15]Tanaka Y,Nishida N,Sugiyama M,et al.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C[J].Nat Genet,2009,41(10):1105-1109.

[16]Suppiah V,Moldovan M,Ahlenstiel G,et al.IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy[J].Nat Genet,2009,41(10):1100-1104.

[17]Rauch A,Kutalik Z,Descombes P,et al.Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure:a genome-wide association study[J].Gastroenterology,2010,138(4):1338-1345.

[18]Thomas DL,Thio CL,Martin MP,et al.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus[J].Nature,2009,461(7265):798-801.

[19]Grebely J,Petoumenos K,Hellard M,et al.Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection[J].Hepatology,2010,52(4):1216-1224.

[20]Rouch A,Rohrbach J,Bochuel PY,et al.The recent break throughs in the understanding of host genomics in hepatitis C[J].Eur J Clin Invest,2010,40(1):950-959.

[21]Sarasin-Filipowicz M,Oakeley EJ,Duong FH,et al.Interferon signaling and treatment outcome in chronic hepatitis C[J].Proc Natl Acad Sci U S A,2008,105(19):7034-7039.

[22]Urban TJ,Thompson AJ,Bradrick SS,et al.IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C[J].Hepatology,2010,20[Epub ahead of print].

施引文献

资源附件(0)

访问统计